Over the past decades, there has been a rapid increase in the incidence and prevalence of
inflammatory bowel disease (IBD) in Asia. The natural history of IBD in Asian patients could …

Crohn's disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel
disease (IBD), are chronic, systemic autoimmune diseases. As the incidence of IBD rapidly …

ABSTRACT Introduction:'Treat-to-target'paradigms in Crohn's disease (CD) directed at
suppressing intestinal inflammation require accurate and reliable measures of disease …

Introduction Dose escalation is one of the treatment approaches studied and suggested in
advanced therapies for Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to …

Background Infliximab and adalimumab are widely used for the treatment of Crohn's disease
and ulcerative colitis. Aim To compare the long-term efficacy and safety of infliximab and …

Introduction The therapeutic armamentarium for managing Crohn's disease (CD) has
expanded significantly in recent decades. Several biologics with three different mechanisms …

Loss of response to antitumor necrosis factor (anti-TNF) therapies in inflammatory bowel
disease occurs in a high proportion of patients. Our aim was to evaluate the loss of response …

Historically, the evaluation of patients with Crohn's disease (CD) has centered on use of
subjective symptom-based assessment. However, patients with CD experience a broad …

Abstract Background and Aim The clinical impact of perianal Crohn's disease (CD)(pCD), a
well‐known poor prognostic factor of CD, has not been fully evaluated in Asian patients. We …

Methods Patients diagnosed with CD between January 2009 and September 2019 were
prospectively enrolled. They were divided into two cohorts according to the year of diagnosis …